Drug Profile


Alternative Names: APC2; MB 102; MP-3180; PP 2338

Latest Information Update: 12 Oct 2016

Price : $50

At a glance

  • Originator Mallinckrodt Inc.
  • Developer MediBeacon
  • Class Diagnostic agents; Pyrazines; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute kidney injury

Most Recent Events

  • 12 Oct 2016 Chemical structure information added
  • 01 Jul 2016 Phase-II clinical trials in Acute kidney injury (Diagnosis) in USA (IV) (NCT02772276)
  • 01 Mar 2014 Phase-I/II clinical trials in Acute kidney injury (Diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top